These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 10528204)

  • 21. Clonal diversity of cytotoxic T lymphocytes that recognize autologous oral squamous cell carcinoma.
    Kobayashi J; Hirohashi Y; Torigoe T; Michifuri Y; Yamamoto T; Tamura Y; Kamiguchi K; Miyazaki A; Yamaguchi A; Hariu H; Hiratsuka H; Sato N
    Hum Immunol; 2009 Feb; 70(2):89-95. PubMed ID: 19124056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of a MAGE-1-derived HLA-A24 epitope-specific CTL line from a Japanese metastatic melanoma patient.
    Akiyama Y; Maruyama K; Tai S; Komiyama M; Iizuka A; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Anticancer Res; 2009 Feb; 29(2):647-55. PubMed ID: 19331215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
    Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
    Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of natural antigenic peptides of a human gastric signet ring cell carcinoma recognized by HLA-A31-restricted cytotoxic T lymphocytes.
    Suzuki K; Sahara H; Okada Y; Yasoshima T; Hirohashi Y; Nabeta Y; Hirai I; Torigoe T; Takahashi S; Matsuura A; Takahashi N; Sasaki A; Suzuki M; Hamuro J; Ikeda H; Wada Y; Hirata K; Kikuchi K; Sato N
    J Immunol; 1999 Sep; 163(5):2783-91. PubMed ID: 10453022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
    Peoples GE; Anderson BW; Lee TV; Murray JL; Kudelka AP; Wharton JT; Ioannides CG
    Clin Cancer Res; 1999 Dec; 5(12):4214-23. PubMed ID: 10632363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Establishment of shared antigen reactive cytotoxic T lymphocyte using co-stimulatory molecule introduced autologous cancer cells.
    Hirohashi Y; Torigoe T; Hirai I; Tamura Y; Nakatsugawa M; Inoue Y; Kanaseki T; Kamiguchi K; Ikeda H; Sasaki A; Yamanaka N; Sato N
    Exp Mol Pathol; 2010 Feb; 88(1):128-32. PubMed ID: 19818766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
    Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generation of cytotoxic T lymphocytes specific for B-cell acute lymphoblastic leukemia family-shared peptides derived from immunoglobulin heavy chain framework region.
    Liu Y; Zhu P; Hu YM
    Chin Med J (Engl); 2007 Apr; 120(8):652-7. PubMed ID: 17517179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Generation of HER2 specific, HLA-A24 restricted CTLs derived from gastric cancer patients].
    Mimura K; Kono K; Sugai H; Miyagawa N; Omata H; Fujii H; Matsumoto Y
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1802-4. PubMed ID: 14619524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
    Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
    Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
    Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
    Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
    Bae J; Martinson JA; Klingemann HG
    Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
    Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients.
    Suefuji Y; Sasatomi T; Shichijo S; Nakagawa S; Deguchi H; Koga T; Kameyama T; Itoh K
    Br J Cancer; 2001 Apr; 84(7):915-9. PubMed ID: 11286471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.
    Matsueda S; Yao A; Ishihara Y; Ogata R; Noguchi M; Itoh K; Harada M
    Prostate; 2004 Aug; 60(3):205-13. PubMed ID: 15176050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The characteristics of anti-B-cell malignance cytotoxic T lymphocytic clones induced by lymphoma relative peptides].
    Guo XL; Zhu P; Zhu X; Liu J; Ou Y; Du JW
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1476-80. PubMed ID: 16061026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL; Crew MD; Santin AD; O'Brien TJ; Cannon MJ
    Clin Cancer Res; 2005 May; 11(9):3446-54. PubMed ID: 15867247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.